GET DAILY SIGNALSNovartis (NVS) Advances +13.6% in 30 Days: Sector Tailwinds and Growth Drivers
Key Takeaways
- Novartis (NVS) shares climbed roughly 13.6% over the past 30 days, rising from about $143.11 to $162.55.
- The advance gained momentum from mid-October onward and accelerated into early November, coinciding with the pharmaceutical sector's third-quarter earnings season.
- Over the full quarter, the stock is up a more modest 5% or so, reflecting a sharp early-September drawdown followed by a sustained multi-week recovery.
- Novartis operates as a pure-play innovative medicines company following its 2023 separation of the Sandoz generics and biosimilars business.
- Core growth continues to be led by franchises including Cosentyx, Kisqali, Kesimpta, and the radiopharmaceutical (Pluvicto) platform.
- Key investor considerations include pipeline momentum, US loss-of-exclusivity dynamics (notably Entresto), and healthcare defensive positioning.
Company Background and Strategic Focus
Novartis AG is a Swiss multinational pharmaceutical company headquartered in Basel, Switzerland. Its American Depositary Receipts trade on the New York Stock Exchange under the ticker NVS. After spinning off its Sandoz generics and biosimilars unit in 2023, the company now operates as a focused pure-play innovative medicines business.
Novartis develops therapies across cardiovascular, renal and metabolic, immunology, neuroscience, oncology, and hematology areas. Standout products include Cosentyx in immunology, Entresto for heart failure, Kesimpta for multiple sclerosis, Kisqali for breast cancer, Leqvio for cholesterol management, and Pluvicto as a targeted radioligand therapy for prostate cancer. The firm continues to invest in next-generation platforms such as radioligand and gene therapies. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Recent Price Action: 30-Day Surge Versus Quarterly View
Over the last 30 days, NVS shares moved from a closing level near $143.11 to roughly $162.55, for a gain of approximately 13.6%. The advance was not entirely steady; the stock held in the low-to-mid $140s through the first half of October before breaking higher around mid-month and extending gains into early November.
Looking at the full quarter, performance appears more measured. Three months earlier the shares traded near the mid-$150s, placing the quarterly advance at about 5%. That figure conceals notable volatility, including a sharp pullback in early September that took the price toward the $137 area before a steady recovery took hold.
Factors Supporting the Recent Advance
The 30-day move picked up pace as the broader pharmaceutical sector entered third-quarter earnings season in late October. Attention on sales growth, margin trends, and forward guidance tends to intensify during this window, and NVS recorded its strongest daily gains in mid-October and again in late October into early November. I’m watching this closely as renewed interest around sector results appeared to support buying.
Defensive characteristics of healthcare also drew some inflows amid broader market rotations. Within Novartis, ongoing momentum in key growth products such as Cosentyx, Kisqali, Kesimpta, and the Pluvicto platform remained central to the narrative, while productivity initiatives added support.
Quarterly Path: Recovery After Early Weakness
The quarterly trend reflected two clear phases. A sharp single-session drop in early September moved the stock from the mid-to-high $150s down toward $137. From those levels the shares mounted a durable recovery that carried through September and October and reached multi-month highs in November.
That rebound drew on improving sentiment in healthcare, continued execution across priority brands, and investor focus on the pipeline and radiopharmaceutical expansion. As one of the larger innovative-medicines companies globally, NVS also benefited from its defensive profile during periods of market uncertainty.
Looking Ahead: Key Areas to Monitor
Several elements are likely to influence the path for NVS shares going forward. Earnings results and management commentary will stay front of mind, especially around growth rates in Cosentyx, Kisqali, Kesimpta, and Pluvicto. Progress on the US loss-of-exclusivity timeline for Entresto and the ability to offset that pressure with newer launches also matter. Pipeline updates in oncology, immunology, and radioligand therapy, along with regulatory decisions and macroeconomic factors such as interest-rate expectations and currency moves, remain relevant considerations.
Exploring AI-Driven Trading Approaches
In my view, data-driven tools can add useful perspective when evaluating market activity. Tickeron’s Trending AI Robots page surfaces a selection of AI-powered trading bots drawn from a broader universe, highlighting only top-performing and most relevant strategies. Each approach differs in timeframe and methodology, so reviewing them individually makes sense before any application. From what I see, this kind of resource offers a practical starting point for traders interested in systematic insights across multiple tickers.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
NVS in upward trend: 10-day moving average moved above 50-day moving average on October 22, 2026
The 10-day moving average for NVS crossed bullishly above the 50-day moving average on October 22, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 69%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 14, 2026. You may want to consider a long position or call options on NVS as a result. In 43 of 80 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 54%.
NVS moved above its 50-day moving average on October 15, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +3.80% 3-day Advance, the price is estimated to grow further. Considering data from situations where NVS advanced for three days, in 187 of 339 cases, the price rose further within the following month. The odds of a continued upward trend are 55%.
The Aroon Indicator entered an Uptrend today. In 162 of 318 cases where NVS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 51%.
Bearish Trend Analysis
The 10-day RSI Indicator for NVS moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 37 similar instances where the indicator moved out of overbought territory. In 20 of the 37 cases, the stock moved lower in the following days. This puts the odds of a move lower at 54%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 17 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The 50-day moving average for NVS moved below the 200-day moving average on October 07, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
NVS broke above its upper Bollinger Band on October 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 4 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 59, placing this stock better than average.
The Tickeron PE Growth Rating for this company is 13 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 33 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 40 (best 1 - 100 worst), indicating steady price growth. NVS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 54 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.437) is normal, around the industry mean (-1.360). P/E Ratio (24.370) is within average values for comparable stocks, (21.695). Projected Growth (PEG Ratio) (3.441) is also within normal values, averaging (5.738). NVS has a moderately high Dividend Yield (0.117) as compared to the industry average of (0.038). P/S Ratio (4.715) is also within normal values, averaging (4.033).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of health care and nutritional products
Industry PharmaceuticalsMajor
Advertisement